

GLP-1 & GIP Receptor Agonists

| Class/Main Action | Name | Dose Range | Considerations |
|--|--------------------------------------|--|--|
| GLP-1 Receptor Agonist (GLP-1 RA) “Incretin Mimetic” <ul style="list-style-type: none"> Increases insulin release with food Slows gastric emptying Promotes satiety Suppresses glucagon | exenatide (Byetta) | 5 and 10 mcg BID | Side effects for all: Nausea, vomiting, weight loss, injection site reaction. Report signs of acute pancreatitis (severe abdominal pain, vomiting), stop med. Increase dose monthly to achieve targets. Black box warning: Thyroid C-cell tumor warning (avoid if family history of medullary thyroid tumor). *Significantly reduces risk of CV death, heart attack, and stroke. †Approved for pediatrics 10-17 yrs Lowers A1c 0.5 – 1.6% Weight loss of 1.6 to 6.0 kgs |
| | exenatide XR [†] (Bydureon) | 2 mg 1x a week Pen injector - Bydureon BCise | |
| | liraglutide (Victoza)* [†] | 0.6, 1.2 and 1.8 mg daily | |
| | dulaglutide* (Trulicity) | 0.75, 1.5, 3.0 and 4.5 mg 1x a week pen injector | |
| | lixisenatide (Adlyxin) | 10 mcg 1x a day for 14 days 20 mcg 1x day starting day 15 | |
| | semaglutide* (Ozempic) | 0.25, 0.5, 1.0 and 2.0 mg 1x a week pen injector | |
| | (Rybelsus) Oral tablet | 3, 7, and 14 mg daily in a.m. Take on empty stomach w/H2O sip | |
| Dual Incretin Agonist Combines both GLP-1 and GIP Incretins. Same action profile as GLP-1 RA, with more intensive action profile. | Tirzepatide (Mounjaro) | 2.5, 5.0, 7.5, 10, 12.5 and 15 mg 1x a week prefilled single dose pen Increase dose by 2.5 mg once monthly to reach targets. | Side effects include: Nausea, diarrhea, injection site reactions. Avoid if family history medullary thyroid tumor. Report pancreatitis. Lowers A1C ~ 1.8 - 2.4% Weight loss of ~ 5.4 – 10 kgs |

Insulin/Injectable Combos

PocketCards updated annually. Download FREE
CDCES Coach App for latest updates and notifications.



| Name | Combines | Considerations |
|---|--|---|
| IDegLira* Xultophy 100/3.6 | Insulin degludec (IDeg or Tresiba) Ultra long insulin + Liraglutide (Victoza) GLP-1 Receptor Agonist (GLP-1 RA) | Xultophy 100/3.6 pre-filled pen = 100 units IDeg / 3.6 mg liraglutide per mL Once daily injection – Dose range 10 to 50 = 10 – 50 units IDeg + 0.36 -1.8 mg liraglutide Recommended starting dose: <ul style="list-style-type: none">• 16 IDegLira (= 16 units IDeg + 0.58 mg liraglutide) Titrate dose up or down by 2 units every 3-4 days to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 21 days. |
| iGlarLixi* Soliqua 100/33 | Insulin glargine (Lantus) Basal Insulin + Lixisenatide (Adlyxin) GLP-1 Receptor Agonist | Soliqua 100/33 Solostar Pen = 100 units glargine / 33 µg lixisenatide per mL Once daily injection an hour prior to first meal of day. Dose range 15 – 60 = 15-60 units glargine + 5 – 20µg lixisenatide Recommended starting dose: <ul style="list-style-type: none">• 15 units if not meeting glucose target on 30 units basal insulin or GLP-1 RA• 30 units if not meeting glucose target on 30-60 units basal insulin or GLP-1 RA Titrate dose up or down by 2-4 units every week to reach target. Supplied in package of five single-use 3mL pens. Once opened, good for 14 days. |

***Discontinue basal insulin /GLP-1 RA therapy before starting. If dose missed, resume with next usual scheduled dose.**

Observe precautions of each component drug.